Caris Life Sciences/$CAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Caris Life Sciences
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Ticker
$CAI
Sector
Primary listing
Employees
1,769
Headquarters
Website
CAI Metrics
BasicAdvanced
$9.5B
-
-$18.57
-
-
Price and volume
Market cap
$9.5B
52-week high
$42.50
52-week low
$25.40
Average daily volume
635K
Financial strength
Current ratio
9.241
Quick ratio
8.561
Long term debt to equity
90.879
Total debt to equity
92.51
Interest coverage (TTM)
-2.94%
Profitability
EBITDA (TTM)
-140.776
Gross margin (TTM)
53.86%
Net profit margin (TTM)
-52.27%
Operating margin (TTM)
-32.56%
Revenue per employee (TTM)
$300,000
Management effectiveness
Valuation
Price to revenue (TTM)
2.711
Price to book
20.89
Price to tangible book (TTM)
21.82
Price to free cash flow (TTM)
-10.295
Free cash flow yield (TTM)
-9.71%
Free cash flow per share (TTM)
-3.27
Growth
What the Analysts think about CAI
Analyst ratings (Buy, Hold, Sell) for Caris Life Sciences stock.
Bulls say / Bears say
Caris posted Q2 2025 revenue of $181.4 million, reflecting an 81% year-over-year jump led by an 86% increase in molecular profiling services, supported by higher case volumes and improved average selling prices (Investing.com).
The company expanded gross margin to 62.7% in Q2 2025 from 37.5% a year earlier, highlighting strong operating leverage as scale increases (Investing.com).
Caris generated positive adjusted EBITDA of $16.7 million and free cash flow of $5.9 million in Q2 2025, reaching a key cash flow turning point and reducing reliance on outside funding (Investing.com).
Despite operational improvements, Caris posted a net loss of $71.8 million in Q2 2025, underscoring persistent profitability issues even as revenue rises (Investing.com).
As of June 30, 2025, the company held $373.7 million in debt, which could limit financial flexibility and add to interest costs (Comtex via pr.comtex.com).
Caris’s IPO valuation was roughly $7.9 billion, putting its price-to-sales ratio near 20× for 2024 revenue, which presents valuation risk if growth slows (WSJ).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
CAI Financial Performance
Revenues and expenses
CAI Earnings Performance
Company profitability
CAI News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Caris Life Sciences stock?
Caris Life Sciences (CAI) has a market cap of $9.5B as of September 17, 2025.
What is the P/E ratio for Caris Life Sciences stock?
The price to earnings (P/E) ratio for Caris Life Sciences (CAI) stock is 0 as of September 17, 2025.
Does Caris Life Sciences stock pay dividends?
No, Caris Life Sciences (CAI) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Caris Life Sciences dividend payment date?
Caris Life Sciences (CAI) stock does not pay dividends to its shareholders.
What is the beta indicator for Caris Life Sciences?
Caris Life Sciences (CAI) does not currently have a Beta indicator.